Baird served as a co-manager on this offering
AboutTESARO, Inc. (“TESARO” or the “Company”) (NASDAQ: TSRO) recently completed a follow-on offering of 3,200,000 shares of common stock at a price of $31.50 per share, generating gross proceeds of approximately $100.8 million. The Company intends to use the net proceeds from the offering to fund its development programs, including clinical trials for its product candidates, rolapitant, niraparib and TSR-011; and for working capital and general corporate purposes.
TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. TESARO has in-licensed and is currently developing three product candidates, rolapitant (Phase 3), niraparib (Phase 3) and TSR-011 (Phase 1/2a). TESARO is headquartered in Waltham, Massachusetts.
For additional information about this transaction, please contact:
- January 2014
- TESARO, Inc.
- Target Location
- North America